Diagnostic Frequency, Response to Therapy, and Long-Term Prognosis among Horses and Ponies with Pituitary Par Intermedia Dysfunction, 1993-2004

Journal of Veterinary Internal Medicine

Volumn 26, Issue 4, 2012, Pages 1027-1034

  Rohrbach, B W ^a   Stafford, J R ^a   Clermont, R S W ^a,f   Reed, S M ^b,d   Schott, H C ^c   Andrews, F M ^a,e  

^a UNIVERSITY OF TENNESSEE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d ROOD AND RIDDLE EQUINE HOSPITAL   (United States)

^e LOUISIANA STATE UNIVERSITY   (United States)

^f Veterinary Teaching Hospital   (United States)

Author keywords

Epidemiology; Equine; Metabolic disease; Pituitary par intermedia dysfunction

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HORSE; HORSE DISEASE; HYPOPHYSIS DISEASE; HYPOPHYSIS INTERMEDIATE LOBE; KAPLAN MEIER METHOD; MALE; PATHOPHYSIOLOGY; PROGNOSIS; QUESTIONNAIRE; RETROSPECTIVE STUDY; SURVIVAL;

ANIMALS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HORSE DISEASES; HORSES; KAPLAN-MEIER ESTIMATE; MALE; PITUITARY DISEASES; PITUITARY GLAND, INTERMEDIATE; PROGNOSIS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

ANIMALIA; EQUIDAE;

EID: 84863991546     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2012.00932.x     Document Type: Article

References (35)

1. Toribio RE. Diagnosing equine pars intermedia dysfunction: Are we there yet? J Vet Intern Med 2005;19:145-146.
2. McCue PM. Equine Cushing's disease. Vet Clin North Am Equine Pract 2002;18:533-543.
3. Love S. Equine Cushing's disease. Br Vet J 1993;149:139-153.
4. Beech J, Garcia M. Hormonal response to thyrotropin-releasing hormone in healthy horses and in horses with pituitary adenoma. Am J Vet Res 1985;46:1941-1943.
5. Eiler H, Oliver JW, Andrews FM, et al. Results of a combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma. J Am Vet Med Assoc 1997;211:79-81.
6. Keen JA, McLaren M, Chandler KJ, McGorum BC. Biochemical indices of vascular function, glucose metabolism and oxidative stress in horses with equine Cushing's disease. Equine Vet J 2004;36:226-229.
7. Donaldson MT, McDonnell SM, Schanbacher BJ, et al. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. J Vet Intern Med 2005;19:217-222.
8. McGowan CM, Frost R, Pfeiffer DU, Neiger R. Serum insulin concentrations in horses with equine Cushing's syndrome: Response to a cortisol inhibitor and prognostic value. Equine Vet J 2004;36:295-298.
9. Perkins GA, Lamb S, Erb HN, et al. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine Vet J 2002;34:679-685.
10. Davis JL, Kirk LM, Davidson GS, Papich MG. Effects of compounded and storage conditions on stability of pergolide mesylate. J Am Vet Med Assoc 2009;234:385-389.
11. Dillman DA. Mail and Internet Surveys; The Tailored Design Method. 2nd ed. Hoboken NJ: Wiley; 2007.
12. Schott HC, Coursen CL, Eberhart SW, et al. The Michigan Cushing's project. In: Proceedings of the 47th Annual Convention of the American Association of Equine Practitioners; 2001:22-4.
13. Duncan JR, Prasse KW. Veterinary Laboratory Medicine, Clinical Pathology, 2nd ed. Ames, IA: Iowa State University Press; 1986:229-234.
14. Couetil L, Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med 1996;10:1-6.
15. Frank N, Andrews FM, Sommardahl CS, et al. Evaluation of the combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses. J Vet Intern Med 2006;20:987-993.
16. Hillyer M, Taylor FGR, Mair TS, et al. Diagnosis of hyperadrenocorticism in the horse. Equine Vet Educ 1992;4:131-134.
17. Dybdal NO, Hargreaves KM, Madigan JE, et al. Diagnostic testing for pituitary pars intermedia dysfunction in horses. J Am Vet Med Assoc 1994;204:627-632.
18. Gribble DH. The endocrine system. In: Catcott EJ, Smithcors JF, eds. Equine Medicine and Surgery, 2nd ed. Wheaton, IL: American Veterinary Publications; 1972: 433-57.
19. Heinrichs M, Baumgartner W, Capen CC. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses. Vet Pathol 1990;27:419-25.
20. Donaldson MT, LaMonte BH, Morresey P, et al. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). J Vet Intern Med 2002;16:742-746.
21. McGowan CM, Neiger R. Efficacy of trilostane for the treatment of equine Cushing's syndrome. Equine Vet J 2003;35:414-418.
22. Donaldson MT, Jorgensen AJ, Beech J. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis. J Am Vet Med Assoc 2004;224:1123-1127.
23. Dybdal N. Pituitary pars intermedia dysfunction (equine Cushing's-like disease) In: Robinson N, ed. Current Therapy in Equine Medicine, 4th ed. Philadelphia, PA: WB Saunders; 1997:449-501.
24. Loeb WF, Capen CC, Johnson LE. Adenomas of the pars intermedia associated with hyperglycemia and glycosuria in two horses. Cornell Vet 1966;56:623-639.
25. van der Kolk JH, Kalsbeek HC, van Garderen E, et al. Equine pituitary neoplasia: A clinical report of 21 cases (1990-1992). Vet Rec 1993;133:594-597.
26. Eyre P, Elmes PJ, Strickland S. Corticosteroid-potentiated vascular responses of the equine digit: A possible pharmacologic basis for laminitis. Am J Vet Res 1979;40:135-138.
27. van der Kolk JH WT, Kalsbeek HC, Breukink HJ. Laboratory diagnosis of equine pituitary pars intermedia adenoma. Domest Anim Endocrinol 1995;12:35-39.
28. Schott HC. Pituitary pars intermedia dysfunction: Equine Cushing's disease. Vet Clin North Am 2002;18:237-270.
29. Green EM, Hunt EL. Hypophyseal neoplasia in a pony. Compend Contin Educ Pract Vet 1985;7:S249-57.
30. van der Kolk J. Equine Cushing's disease. Equine Vet Educ 1997;9:209-214.
31. Aleman M, Watson JL, Williams DC, et al. Myopathy in horses with pituitary pars intermedia dysfunction (Cushing's disease). Neuromuscul Disord 2006;16:737-744.
32. Field JR, Wolf C. Cushing's syndrome in a horse. Equine Vet J 1988;20:301-4.
33. Cohen ND, Carter GK. Steroid hepatopathy in a horse with glucocorticoid-induced hyperadrenocorticism. J Am Vet Med Assoc 1992;200:1682-4.
34. Johnson SE, Scherding RG. Diseases of the liver and biliary tract. In: Birchard SJ, Scherding RG, eds. Saunders Manual of Small Animal Practice, 2nd ed. Philadelphia, PA: WB Saunders; 2000:824-73.
35. Schott HC, Graves EA, Refsal KR, et al. Diagnosis and treatment of pituitary pars intermedia dysfunction (classical Cushing's disease) and metabolic syndrome (peripheral Cushing's syndrome) in horses. Proceedings of the 5th World World Cong Vet Derm 2005;5:159-169.